The stock's rise snapped a four-day losing streak.
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Investing.com -- Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug ...
4d
Investing News Network on MSNStem Cell Stocks: 10 Biggest NASDAQ Companies in 2025Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results